Bank of New Hampshire Has $911,000 Holdings in DexCom, Inc. (NASDAQ:DXCM)

Bank of New Hampshire lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 6.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,713 shares of the medical device company’s stock after selling 748 shares during the period. Bank of New Hampshire’s holdings in DexCom were worth $911,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Nordea Investment Management AB lifted its stake in shares of DexCom by 2.8% in the 4th quarter. Nordea Investment Management AB now owns 80,590 shares of the medical device company’s stock valued at $6,271,000 after purchasing an additional 2,183 shares during the last quarter. GAMMA Investing LLC raised its holdings in DexCom by 47.6% in the 4th quarter. GAMMA Investing LLC now owns 8,258 shares of the medical device company’s stock worth $642,000 after acquiring an additional 2,665 shares during the period. Versant Capital Management Inc bought a new position in DexCom in the 4th quarter worth $25,000. B. Riley Wealth Advisors Inc. raised its holdings in DexCom by 42.3% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 5,590 shares of the medical device company’s stock worth $370,000 after acquiring an additional 1,662 shares during the period. Finally, Tidal Investments LLC raised its holdings in DexCom by 68.0% in the 3rd quarter. Tidal Investments LLC now owns 36,742 shares of the medical device company’s stock worth $2,463,000 after acquiring an additional 14,872 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Price Performance

NASDAQ:DXCM traded up $0.30 during mid-day trading on Tuesday, hitting $80.18. The company’s stock had a trading volume of 119,229 shares, compared to its average volume of 2,122,014. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company has a market capitalization of $31.32 billion, a price-to-earnings ratio of 48.01, a P/E/G ratio of 2.46 and a beta of 1.12. The stock has a fifty day moving average of $76.28 and a 200-day moving average of $79.78.

Analyst Upgrades and Downgrades

Several brokerages recently commented on DXCM. Wells Fargo & Company lifted their target price on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Raymond James dropped their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Citigroup lifted their target price on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. upped their price objective on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average target price of $98.00.

Insider Buying and Selling

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.